OrthoPediatrics (KIDS) Competitors

Enovis (NYSE:ENOV) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation.

Does the MarketBeat Community prefer ENOV or KIDS?

OrthoPediatrics received 282 more outperform votes than Enovis when rated by MarketBeat users. However, 66.04% of users gave Enovis an outperform vote while only 64.56% of users gave OrthoPediatrics an outperform vote.

Company	Underperform	Outperform
Enovis	Outperform Votes 35 66.04%	Underperform Votes 18 33.96%
OrthoPediatrics	Outperform Votes 317 64.56%	Underperform Votes 174 35.44%

Does the media refer more to ENOV or KIDS?

In the previous week, Enovis had 3 more articles in the media than OrthoPediatrics. MarketBeat recorded 8 mentions for Enovis and 5 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 1.32 beat Enovis' score of 1.10 indicating that OrthoPediatrics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OrthoPediatrics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, ENOV or KIDS?

Enovis has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.

Do analysts rate ENOV or KIDS?

Enovis presently has a consensus price target of $58.00, indicating a potential upside of 78.95%. OrthoPediatrics has a consensus price target of $35.83, indicating a potential upside of 64.00%. Given Enovis' higher probable upside, analysts clearly believe Enovis is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
OrthoPediatrics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Is ENOV or KIDS more profitable?

Enovis has a net margin of -5.95% compared to OrthoPediatrics' net margin of -15.00%. Enovis' return on equity of 4.39% beat OrthoPediatrics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-5.95%	4.39%	2.80%
OrthoPediatrics	-15.00%	-5.78%	-4.80%

Do institutionals and insiders believe in ENOV or KIDS?

98.4% of Enovis shares are held by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are held by institutional investors. 2.7% of Enovis shares are held by company insiders. Comparatively, 32.7% of OrthoPediatrics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has preferable earnings & valuation, ENOV or KIDS?

OrthoPediatrics has lower revenue, but higher earnings than Enovis. OrthoPediatrics is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.15B	0.86	-$33.26M	-$13.95	-2.32
OrthoPediatrics	$212.45M	2.50	-$20.97M	-$1.75	-12.49

Summary

Enovis beats OrthoPediatrics on 10 of the 18 factors compared between the two stocks.